Fennec Pharmaceuticals is a biopharmaceutical company focused on its product candidate, PEDMARK® (sodium thiosulfate injection), which is used to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Co. has established Fennec HEARS, a single source program designed to connect PEDMARK® patients to both patient financial and product access support. The program provides assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. The FENC YTD return is shown above.
The YTD Return on the FENC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FENC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FENC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|